0001415889-23-008425.txt : 20230519 0001415889-23-008425.hdr.sgml : 20230519 20230519180025 ACCESSION NUMBER: 0001415889-23-008425 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230517 FILED AS OF DATE: 20230519 DATE AS OF CHANGE: 20230519 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gillies Hunter CENTRAL INDEX KEY: 0001868997 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40544 FILM NUMBER: 23941802 MAIL ADDRESS: STREET 1: C/O AEROVATE THERAPEUTICS, INC. STREET 2: 200 BERKELEY STREET, FLOOR 18 CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aerovate Therapeutics, Inc. CENTRAL INDEX KEY: 0001798749 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 831377888 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 930 WINTER STREET STREET 2: SUITE M-500 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-443-2400 MAIL ADDRESS: STREET 1: 930 WINTER STREET STREET 2: SUITE M-500 CITY: WALTHAM STATE: MA ZIP: 02451 4 1 form4-05192023_060504.xml X0407 4 2023-05-17 0001798749 Aerovate Therapeutics, Inc. AVTE 0001868997 Gillies Hunter C/O AEROVATE THERAPEUTICS, INC. 930 WINTER STREET, SUITE M-500 WALTHAM MA 02451 false true false false CHIEF MEDICAL OFFICER 1 Common Stock 2023-05-17 4 M 0 1090 1.74 A 4341 D Common Stock 2023-05-17 4 S 0 1090 19.5925 D 3251 D Stock Option (Right to Buy) 1.74 2023-05-17 4 M 0 1090 0 D 2030-09-03 Common Stock 1090 19018 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023. Includes 1,291 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2023 in a transaction that is exempt under Rule 16b-3(c) and 16b3(d). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.50 to $19.665, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. /s/ George A. Eldridge, Attorney-in-Fact 2023-05-19